Artiam Bio Inc.
Publicly observedCary, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Cary | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Artiam Bio Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | FKJAXBQEDUJ8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model
USD 279,513.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model
USD 292,279.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.